1. CE: HIV-Associated Kaposi Sarcoma in the Combination Antiretroviral Therapy Era.
- Author
-
Mangusan RF, Ekwede I, and Widell A
- Subjects
- Male, Humans, Antiretroviral Therapy, Highly Active adverse effects, Sarcoma, Kaposi drug therapy, Sarcoma, Kaposi epidemiology, Sarcoma, Kaposi etiology, Herpesvirus 8, Human, AIDS-Related Opportunistic Infections drug therapy, AIDS-Related Opportunistic Infections epidemiology, AIDS-Related Opportunistic Infections complications, HIV Infections complications, HIV Infections drug therapy
- Abstract
Abstract: Kaposi sarcoma is a tumor caused by Kaposi sarcoma herpesvirus, also known as human herpesvirus 8. Its occurrence is associated with an immunocompromised state. Kaposi sarcoma that occurs among people living with HIV (PLWH) is known as epidemic Kaposi sarcoma. Despite the decline in HIV-associated complications because of the introduction of combination antiretroviral therapy two decades ago, Kaposi sarcoma continues to affect PLWH worldwide. It affects young African American men more than other age and racial groups and can result in multiorgan dysfunction, leading to short-term and chronic debilitating symptoms as well as death. While some patients with epidemic Kaposi sarcoma are managed as outpatients, others may require higher levels of care and their acuity may fluctuate throughout their life span. Therefore, nurses, regardless of their specialty, may experience caring for a patient with epidemic Kaposi sarcoma at some point in their career. Learning about this condition and the needs of patients who have it will help nurses provide effective care. Here, the authors describe Kaposi sarcoma in general as well as the epidemiology, characteristics, and management of epidemic Kaposi sarcoma. They also describe specific nursing considerations in the care of PLWH who have the disease., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF